Eli Lilly & (LLY) Stock
Major pharmaceutical group with diabetes and obesity medicines. Here's the price, business snapshot, and what's worth knowing about Eli Lilly & in August 2026.
Eli Lilly and Company (LLY) is a major US pharmaceutical group with a broad portfolio spanning diabetes, oncology, immunology and neuroscience. With a market capitalisation around $756.8bn, Lilly is known for strong commercial medicines such as GLP-1 and dual-agonist therapies that have driven recent sales growth, alongside a diversified R&D pipeline. Investors should know Lilly combines steady cash-generating marketed products with growth from newer launches and late‑stage candidates, but faces typical sector risks: regulatory review, patent expiries, pricing scrutiny and competition. Financials can be resilient but are sensitive to trial outcomes and reimbursement decisions. As general information, this summary is educational not personal financial advice — returns are not guaranteed and values can fall as well as rise. Prospective investors should consider their objectives, time horizon and risk tolerance, and may wish to consult an authorised financial adviser before investing.
Why It’s Moving
Lilly’s latest earnings beat and pipeline wins are keeping momentum firmly on its side.
- Lilly’s August 5 earnings beat expectations and lifted full-year revenue guidance, signaling that demand for Zepbound and Mounjaro is still accelerating rather than fading.
- The company also highlighted pipeline and regulatory progress, including fresh approvals and submissions that broaden its growth story beyond obesity and diabetes.
- Recent headlines about anti-counterfeit lawsuits and Europe’s first approval of its weight-management pill have kept attention on Lilly’s market share, pricing power, and expansion opportunities.
Lilly’s latest earnings beat and pipeline wins are keeping momentum firmly on its side.
- Lilly’s August 5 earnings beat expectations and lifted full-year revenue guidance, signaling that demand for Zepbound and Mounjaro is still accelerating rather than fading.
- The company also highlighted pipeline and regulatory progress, including fresh approvals and submissions that broaden its growth story beyond obesity and diabetes.
- Recent headlines about anti-counterfeit lawsuits and Europe’s first approval of its weight-management pill have kept attention on Lilly’s market share, pricing power, and expansion opportunities.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for LLY is expected to be October 29, 2026. This report will cover Q3 2026 results, consistent with the company’s usual late-October earnings pattern after its August Q2 release. For an investor briefing, that is the current scheduled timing unless Lilly updates the date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Eli Lilly's stock with a target price of $1,123.22, indicating growth potential.
Financial Health
Eli Lilly is performing strongly with high profits, cash flow, and revenue, indicating robust financial health.
Dividend
Eli Lilly's dividend yield of 0.52% is low, indicating less income potential for investors. If you invested $1000 you would be paid $5.46 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline-led growth
Late-stage candidates and recent product roll-outs can boost revenue, though outcomes and timelines are uncertain and can affect share performance.
Global commercial reach
A wide geographic footprint helps diversify sales, but reimbursement policies and pricing pressure vary by market and may impact returns.
R&D and innovation
Heavy R&D investment fuels long-term potential, while the opposite side of the coin is the cost and risk of trials and regulatory review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
